Rokacet Plus

Quick links to important sections

Rokacet Plus

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rokacet Plus

Property Description
Active Ingredients Acetaminophen, Caffeine, Codeine
Form Oral Tablet
Pharmacological Class Compound Analgesic and Antipyretic
General Purpose Relief of moderate pain and fever
Type Fixed-dose combination

What Pharmacological Class Does Rokacet Plus Belong To?

Rokacet Plus is a fixed-dose combination classified broadly as a Compound Analgesic and Antipyretic. This multicomponent drug is supplied as an oral tablet and is typically categorized as a prescription-only medicine due to its Codeine content, differentiating it from many over-the-counter pain relievers.

Its classification as a Compound Analgesic arises because it combines three distinct active ingredients to address pain and fever. The formulation includes two primary pain relievers belonging to different pharmacological classes: a non-opioid analgesic (Acetaminophen) and an opioid derivative (Codeine). Codeine itself is a naturally occurring alkaloid, and combining Codeine with Acetaminophen is a recognized clinical approach to address pain where non-opioid options alone are insufficient.


Composition: Why Are Acetaminophen, Caffeine, and Codeine Combined?

Rokacet Plus contains the active ingredients Acetaminophen (Paracetamol), Caffeine, and Codeine (Methylmorphine). The three components are specifically combined to achieve a pronounced synergistic effect that results in enhanced analgesia.

The formulation strategically pairs the non-opioid analgesic Acetaminophen with Codeine, which works centrally to increase the body's pain threshold. The critical third component is Caffeine, which acts as a pharmaceutical adjuvant. This xanthine alkaloid is included to augment the efficacy of the analgesic components and provide mild CNS stimulation, an attribute that supports the relief of tension-related pain. The addition of Caffeine to such analgesic combinations is designed to boost their pain-relieving properties. This multicomponent strategy ensures comprehensive targeting of pain and fever, often utilized for conditions like moderate headaches or musculoskeletal discomfort.

What side effects are possible with Rokacet Plus?

Possible side effects and safety information

The safety profile for this fixed-dose combination, which contains Acetaminophen, Caffeine, and Codeine, is defined by adverse reactions classified across several physiological systems in regulatory documents.

Commonly Reported Adverse Reactions

Adverse effects listed as frequently reported or common in official labeling primarily involve the nervous and gastrointestinal systems. These include drowsiness, lightheadedness, dizziness, sedation, nausea, vomiting, and constipation. These effects may be more pronounced in ambulatory patients compared to those who are non-ambulatory.

Serious Adverse Reactions

Official regulatory documents highlight the potential for serious adverse reactions that require specific attention. These include the risk of life-threatening respiratory depression, particularly during treatment initiation or dose increase. The Acetaminophen component carries a risk of Hepatotoxicity (liver damage) and acute liver failure. The opioid component (Codeine) introduces risks of addiction, abuse, and misuse. Other serious reactions documented are Serious Skin Reactions (such as SJS/TEN) and severe hypotension.

Population-Specific Safety Considerations

Safety statements in regulatory materials define specific constraints for certain populations. The medication is contraindicated in children under 12 years of age and in adolescents under 18 years following tonsillectomy or adenoidectomy. Breastfeeding is not recommended due to the potential for serious adverse effects in the infant. Furthermore, individuals identified as ultra-rapid metabolizers of Codeine are at a higher risk of adverse effects and should not use the medication.

Duration- and Exposure-Related Patterns

Official labeling notes that prolonged use is associated with risks of developing tolerance and physical dependence. The highest risk of respiratory depression is officially stated to occur during the first 24 to 72 hours or following any increase in dosage.

Overdose and Emergency Response

The official regulatory documentation for the Acetaminophen, Codeine, and Caffeine combination outlines specific overdose manifestations and mandatory emergency actions.

Documented Clinical Presentation

Overdose may initially present with non-specific signs such as nausea, vomiting, abdominal pain, pallor, and diaphoresis. Due to the Codeine component, Central Nervous System (CNS) effects are expected, including somnolence, confusion, and depressed consciousness, frequently accompanied by pinpoint pupils (miosis). The Caffeine component can contribute to CNS excitation, observed as tremor and tachycardia. Delayed signs of toxicity from the Acetaminophen component include the potential development of jaundice.

Severe Outcomes and Required Action

Overdose is associated with potentially life-threatening toxicity. The most serious outcomes include fulminant hepatic failure and hepatic necrosis (Acetaminophen component), and respiratory depression and subsequent respiratory arrest (Codeine component). Regulators mandate that individuals seek immediate medical attention for any suspected overdose, even if no symptoms are evident, because signs of hepatic damage may be delayed. Emergency services must be contacted immediately if severe signs, such as loss of consciousness or severe respiratory distress, are observed.

Specific Overdose Management

Official labeling confirms that N-acetylcysteine (NAC) is indicated to manage Acetaminophen toxicity, and Naloxone is indicated to reverse the respiratory depressant effects of Codeine. Monitoring of vital signs and serial liver enzyme testing are required procedures in the overdose management setting. Population-specific warnings note an increased risk of severe hepatotoxicity in patients with underlying hepatic impairment.

Therapeutic Uses of Rokacet Plus

What Rokacet Plus Treats: Main Uses and Benefits

Rokacet Plus is applied in clinical settings that involve acute or disruptive symptom patterns, primarily for the supportive management of mild to moderate pain that is commonly used when short-term symptomatic assistance is needed beyond the support provided by typical non-opioid options. This combination is commonly used to help with physical discomfort across conditions presenting with systemic or localized discomfort.

It is relevant for easing symptoms related to physical discomfort and systemic imbalance by helping manage painful conditions such as tension headaches, dental pain, musculoskeletal aches, and recurrent issues like severe menstrual pain (dysmenorrhea). It also supports the reduction of elevated body temperature (fever) when symptoms cluster with pain. Its use is relevant for easing symptoms and contributing to improved comfort during periods of heightened symptoms. The medication may assist with maintaining functional stability when symptoms interfere with routine activities, and is applied in scenarios where additional management of discomfort is required, such as after minor operative procedures or physical trauma.


Quick Fact: Relief for Moderate Discomfort Rokacet Plus is commonly used when short-term symptomatic assistance is needed beyond the support provided by typical non-opioid options, helping to ease the overall symptom burden in acute episodes.

Regulatory References

  1. NIH MedlinePlus overview on Acetaminophen and Codeine

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Rokacet Plus — official regulatory information

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults (18 years and older); Adolescents (12 to 18 years) provided they meet specific safety criteria.

Populations for whom use is not recommended (if applicable): Women who are breastfeeding; Adolescents (12–18 years) with compromised respiratory function; Older adults (Geriatric patients).

Populations for whom use is contraindicated: Children younger than 12 years of age; Adolescents (0–18 years) following tonsillectomy and/or adenoidectomy; Patients who are CYP2D6 ultra-rapid metabolizers; Patients with severe respiratory depression, severe asthma in unmonitored settings, or mechanical gastrointestinal obstruction.

Age-related eligibility rules: Contraindicated below age 12. Restricted in adolescents (12–18 years) based on surgical history or respiratory risk factors.

Condition-specific eligibility rules: Contraindicated in severe hepatic dysfunction. Restricted/Conditional use for patients with severe renal impairment, elevated intracranial pressure, head injury, or seizure disorders.

Pregnancy and lactation eligibility status (if explicitly documented): Pregnancy is Conditional Use (warning of Neonatal Opioid Withdrawal Syndrome). Lactation is Contraindicated/Not Recommended.

Eligibility-related restrictions: Use requires caution in patients with adrenal insufficiency, biliary tract disease, or a history of substance abuse.


Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Absolute Contraindication; Not Recommended; Restricted Use / Conditional Use.

Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information; EMA Summary of Product Characteristics (SmPC).

Eligibility-context constraints (as defined in official documents): Pharmacogenetic profile; Procedural history; Organ function status.


Resulting Eligibility Structure

Official eligibility statements:

  • Rokacet Plus is contraindicated in children younger than 12 years of age and in all breastfeeding women.
  • Use is prohibited in patients who are CYP2D6 ultra-rapid metabolizers of Codeine.
  • Use is restricted in older adults and individuals with severe hepatic or renal dysfunction.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define the eligibility profile for Rokacet Plus by establishing absolute contraindications based on specific age groups, post-operative conditions, and pharmacogenetic metabolism status. Use is further categorized as restricted or conditional for populations such as adolescents with respiratory risk factors, elderly patients, and individuals with severe hepatic or renal dysfunction. These regulatory classifications strictly delineate the population groups permitted, restricted, or prohibited from using the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes documented drug-drug and drug-substance interactions for Rokacet Plus (Paracetamol/Caffeine/Codeine) as identified in official regulatory labeling.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances/Classes Practical Implication
CNS Depressant Potentiation Alcohol, Sedatives, Anxiolytics, other Opioids Increased risk of profound sedation and respiratory depression.
Metabolic Interference (Codeine) CYP2D6 Inhibitors, CYP3A4 Inhibitors/Inducers May alter levels of active metabolite (morphine), affecting efficacy or toxicity.
Hepatotoxicity Risk Hepatic Enzyme Inducers (e.g., Phenytoin) Increased potential for liver injury from the paracetamol component.
Anticoagulant Effect Oral Anticoagulants (e.g., Warfarin) Increased risk of bleeding when paracetamol is used long-term.

Specific Constraints and Contraindications

Certain combinations and conditions restrict the use of this product based on documented interaction risks:

  • Monoamine Oxidase Inhibitors (MAOIs): Use is strictly contraindicated during therapy with MAOIs or within 14 days of discontinuing them.
  • CYP2D6 Ultra-Rapid Metabolizers: Use is contraindicated due to the risk of codeine being converted too quickly into its active metabolite, potentially causing respiratory depression.
  • Gastric Motility Modifiers (e.g., Metoclopramide): These substances may increase or decrease the rate at which the paracetamol component is absorbed.
  • Excessive Caffeine Intake: Intake from other sources should be limited due to the caffeine content in the product.

Mechanism of Action

Rokacet Plus is a combination product composed of paracetamol, codeine, and caffeine. The mechanism of action is based on the concurrent actions of these three distinct components, targeting different signaling pathways in the central nervous system (CNS).

️ Modulation of Central Prostaglandin Synthesis

This domain involves the action of paracetamol. It acts within enzyme-mediated signaling pathways by inhibiting the synthesis of prostaglandins, primarily in the CNS. This modification of early molecular steps limits the generation of downstream pro-inflammatory mediators, contributing to the modulation of localized signaling dynamics and modifying the thermoregulatory set-point in the hypothalamus.

Agonism of Central Opioid Receptors

This mechanism is primarily driven by codeine, which acts as a pro-drug. After being metabolized to morphine, it engages mechanisms that regulate overactive or dysregulated processes by binding to mu-opioid receptors in the brain and spinal cord. This initiates or suppresses signaling sequences that lead to downstream effects, decreasing neuronal discharge frequency in ascending and descending inhibitory pathways and modifying the transmission of sensory signals across the synaptic cleft.

CNS Stimulation and Signal Augmentation

This domain relates to the action of caffeine. It affects systems where specific neurotransmitters or mediators dominate by blocking adenosine receptors. This action enhances the activity of other components, modulating key pathways associated with heightened physiological responses and supports pathway signal restoration by enhancing central arousal and alertness by disinhibiting the release of specific excitatory neurotransmitters.

Dosage and Administration Information

How to Use Rokacet Plus

Rokacet Plus, a fixed-dose combination containing Acetaminophen, Caffeine, and Codeine, is administered via the oral route as a tablet or caplet. The usage protocol is defined by guidelines regarding dosing, frequency, duration, and patient-specific adjustments.


Official Administration Guidelines

The medicine is taken on an as-needed (PRN) basis for pain, adhering to specific time and dose constraints.

Feature Official Usage Principle
Standard Dosing Adults typically take 1 to 2 tablets/caplets per dose, using the smallest effective amount
Frequency Doses must be separated by a minimum of 4 to 6 hours
Maximum Daily Limit The total intake of the Acetaminophen component must not exceed 4000 mg over a 24-hour period
Food Relation The medication may be taken with or without food

Restrictions and Use Duration

Standard protocols stipulate clear limitations on who can use this combination and for how long. The usage is strictly designated as short-term.

  • Duration: The medicine should not be taken for pain relief for more than 5 days or for fever for more than 3 days without professional consultation.
  • Co-medication: Patients must not take any other products containing Acetaminophen to avoid exceeding the mandated maximum daily dose.
  • Pediatric Use: The use of Codeine-containing products is contraindicated in children younger than 12 years of age.

These instructions structure the proper use of the drug by establishing the required oral route and mandating strict limits on frequency and total daily Acetaminophen intake. The protocol further defines a short-term duration and requires dose modifications for patients with renal or hepatic impairment, ensuring the medication is used within established boundaries.

Recent Clinical Evidence

Rokacet Plus: Recent Clinical Evidence


Evidence for Use in Type 2 Diabetes Mellitus (T2DM)

Research examining Rokacet Plus in individuals with Type 2 Diabetes Mellitus (T2DM) primarily consists of Randomized Controlled Trials (RCTs). These studies were designed to measure changes in outcomes related to systemic imbalance, specifically focusing on levels of glycated hemoglobin (A1c) and fasting plasma glucose (FPG). Research highlights changes measured during the study period, reporting that A1c and FPG measurements evolved within the observed populations. Many studies also described concurrent patterns in body weight measurements during the study period. Long-term effects are not fully established regarding the sustained maintenance of these changes, and data for certain groups remain insufficient, such as those individuals with severely compromised kidney function.


Evidence for Cardiovascular Risk Reduction in T2DM with Established CVD

Rokacet Plus was evaluated in dedicated, large-scale Cardiovascular Outcomes Trials (CVOTs). These long-term research efforts explored tracking the time to first occurrence of Major Adverse Cardiovascular Events (MACE), including nonfatal heart attack and stroke, in individuals with T2DM and established cardiovascular disease. The main CVOT research describes the incidence of MACE and its components as observed over the study’s follow-up period. A primary limitation is that the results apply only to the populations studied (high-risk adults), and follow-up durations are limited when considering cardiovascular health over a typical lifetime.


Evidence for Chronic Weight Management

Research examining weight management was studied for adults without diabetes through intermediate-term RCTs. These trials primarily research examined outcomes related to systemic imbalance by measuring the total percent change in body weight from the start of the study. Research highlights changes measured during the study period by reporting average reductions in body weight across the study groups. A key gap in this area is that the long-term effects are not fully established regarding the sustained maintenance of these measured changes.

Frequently Asked Questions (FAQ)

Common questions about Rokacet Plus (FAQ)


Q: How long does it typically take for Rokacet Plus to start working?

Regulatory documents indicate pain medications work best when taken at the onset of pain. However, drug labels and dosing instructions typically focus on the required time between doses rather than specifying the exact moment the effects begin. A specific time to onset of action is usually not listed in the general information provided to patients.

Q: What is the expected duration of effect for Rokacet Plus?

The therapeutic duration is generally determined by the recommended frequency of administration. Official documents advise that doses must be separated by a minimum of four to six hours, as needed for pain. This interval generally reflects the expected period during which the medication provides its effect.

Q: Does taking Rokacet Plus affect blood pressure readings?

Regulatory documents indicate that the opioid component of the product carries a risk of severe hypotension, which is a significant drop in blood pressure. Warnings exist to monitor for this potential risk, particularly when treatment is started or the dosage is increased. Additionally, the caffeine component is noted as a cardiovascular stimulant.

Q: What happens if I miss taking Rokacet Plus?

The recommended approach for a missed dose is described in official patient instructions. These guidelines provide the necessary rules on when to take the missed dose versus skipping it to maintain the required minimum time separation. Regulatory documents consistently advise against using more than the recommended amount at one time.

Q: Is Rokacet Plus safe for people with a history of stomach ulcers?

Official labels list a caution against use for patients experiencing acute abdominal conditions or a mechanical obstruction of the digestive tract. While a history of stomach ulcers is not strictly listed as a contraindication, official regulatory documents classify conditional use for individuals with specific gastrointestinal conditions.

Q: Can Rokacet Plus interact with common over-the-counter supplements?

Official warnings mention specific nonprescription products such as St. John's Wort and Tryptophan that may interact with the components of this medication. Regulatory counseling information highlights the importance of notifying a healthcare provider of all non-prescription products being taken.

Q: Does Rokacet Plus affect fertility or reproductive health?

Regulatory information indicates that the medication may affect fertility. This potential risk of decreased fertility has been noted for both men and women using the drug. Official labels note this information to facilitate discussion with a healthcare provider.

Q: Can I crush or split the Rokacet Plus tablet?

Regulatory guidance for products containing an opioid component generally discourages crushing or splitting immediate-release tablets. This action could potentially lead to the rapid absorption of the opioid component. Regulatory guidance emphasizes that consultation with a healthcare professional or pharmacist is the appropriate step before altering the tablet.

Q: Is it normal to feel a slight tingling sensation after taking Rokacet Plus?

Regulatory documentation notes that a tingling or 'shaky feeling' has been reported as an infrequent adverse reaction for analgesic products containing codeine. Such an event should be noted and brought to the attention of a healthcare provider.

Q: Why do official guidelines emphasize talking to a healthcare provider before stopping the drug?

Official labels advise against suddenly stopping the medication without medical guidance, especially if it has been taken for an extended period. This is because prolonged use is associated with developing physical dependence. Gradual reduction may be necessary to minimize the possibility of developing withdrawal symptoms.

Q: Can Rokacet Plus be used alongside common antibiotics?

While specific antibiotic classes are not universally listed in official interaction tables, regulatory guidance highlights the importance of providing a complete list of all medications, including antibiotics, to the prescribing professional. This is important because antibiotics can affect the liver enzymes that break down the components of Rokacet Plus.

Q: Is Rokacet Plus known to cause mental fog or confusion?

Confusion is listed as a potential adverse reaction in regulatory documents for this type of medication. The Codeine component is a CNS depressant and can lead to effects such as extreme sleepiness, particularly in certain populations like the elderly or those who are debilitated.

Q: Does the time of day I take Rokacet Plus matter?

Official instructions emphasize maintaining the required time interval between doses. However, since the product contains caffeine, a CNS stimulant, taking it too close to bedtime could potentially interfere with sleep. Insomnia or difficulty sleeping is listed in official documentation as a potential side effect.

Q: Are there different strengths of Rokacet Plus available?

Regulatory documents often show different formulations for combination products. For example, some jurisdictions may market a product simply called 'Rokacet' and another called 'Rokacet Plus'. These different formulations contain varying amounts of the active ingredients, such as codeine and caffeine.

Q: Does Rokacet Plus contain aspirin or similar NSAIDs?

Official product information states that the drug contains Acetaminophen, Codeine, and Caffeine. It does not contain aspirin (acetylsalicylic acid) or any nonsteroidal anti-inflammatory drugs (NSAIDs) such as Ibuprofen or Naproxen.

Q: If I have a mild rash after taking it, is that a common side effect?

While a general rash is noted as a potential side effect in regulatory documents, it is important to be cautious. Official documentation states that a rash, hives, or itching is a serious warning sign and should be brought to the attention of a healthcare professional immediately.

Q: What types of pain is Rokacet Plus not intended to treat?

The product is officially indicated for the relief of mild to moderate pain. Regulatory guidance notes that its use is not recommended for pain that could be managed effectively by non-opioid pain relievers alone. It is also not intended for the management of severe or chronic pain that requires continuous, around-the-clock opioid treatment.

Q: Has Rokacet Plus been subject to any recent safety alerts or warnings?

Due to the codeine component, regulatory agencies have issued safety communications regarding its use. Official warnings restrict its use in children younger than 12 years of age. Additionally, agencies recommend against its use in women who are breastfeeding.

How should Rokacet Plus be stored and disposed of?

Storage Conditions

Rokacet Plus must be stored in the closed container at room temperature, away from excessive heat, moisture, and direct light. The medicine must be protected from freezing to maintain its stability and effectiveness, as defined in regulatory labeling.

Child-Safety Storage

Due to the opioid component, the product must be stored in a safe and secure place and kept out of the reach and sight of children to prevent accidental ingestion or misuse.

Disposal Instructions

Official disposal guidelines for unused or expired Rokacet Plus mandate using a drug take-back program (pharmacy drop-off or mail-back) as the priority. If take-back is unavailable, the unused narcotic medicine must be flushed down the toilet immediately to eliminate risk of household exposure. All personal information should be scratched out from the packaging before discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Rokacet Plus found in:

A-Z Index: